Evotec SE and Sandoz AG have formalized a non-binding memorandum of understanding that could transfer Evotec’s Toulouse-based biologics manufacturing arm  Evotec Biologics EU to the Sandoz network for approximately US$300 million in cash. Under the preliminary pact announced from Hamburg, Germany, the deal contemplates a smooth handover of facilities in southern France, subject to customary due diligence, regulatory approvals from the European Medicines Agency (EMA), and other standard closing conditions. The move crystallizes an industry-wide trend in which CDMOs and pharma producers recalibrate asset portfolios to sharpen strategic focus, optimize capital allocation, and address expanding demand for rigorous biologics production under stringent Good Manufacturing Practice (GMP) protocols.

Located on the outskirts of Toulouse, the Just – Evotec Biologics EU campus spans several thousand square meters of cleanroom suites designed for cell culture, upstream processing, downstream purification and fill-finish operations. Equipped with single-use bioreactors up to 2,000 liters and state-of-the-art chromatography skids, the facility supports both clinical-stage and commercial-scale biologics campaigns. With over 150 skilled operators, quality assurance experts and process engineers, the site maintains full GMP accreditation and has capacity to deliver multiple cell-based therapeutics annually. Sandoz, a division of Novartis, would inherit these capabilities and integrate the site into its global network, enhancing throughput for monoclonal antibodies, fusion proteins, and emerging modalities such as biosimilars and novel biotherapeutics.

Biologics demand continues to surge, driven by immuno-oncology, autoimmune and rare disease indications. This growth has exerted pressure on CDMO capacity worldwide, prompting strategic divestitures and acquisitions to streamline operations. Regulatory frameworks in Europe, led by EMA’s evolving guidance on single-use equipment qualification, process validation, and digital batch records, place a premium on flexible, GMP-compliant manufacturing platforms. Outsourcing partnerships are increasingly favored by biotech innovators seeking to manage capital expenditure, accelerate timelines and ensure supply chain resilience. In this context, Evotec’s decision to potentially divest aligns with broader market realignment—CDMOs are scaling up or consolidating to meet sophisticated biologics requirements while sponsors leverage specialist manufacturing partners.

If consummated, the transaction would bolster Sandoz’s CDMO footprint in Europe, positioning it to capture additional contract volume as customers seek turnkey biologics solutions. For Evotec, the proceeds could underwrite investments in its drug discovery services, small-molecule API pipelines or emerging cell and gene therapy collaborations. The deal underscores intensifying competition among CDMOs to offer end-to-end capabilities and highlights the importance of asset agility amid shifting demand. Rival service providers may respond by expanding footprint through greenfield projects or strategic partnerships, while biotech sponsors will monitor capacity availability when selecting outsourcing venues for critical bioprocessing projects.

Why This Matters

This potential divestiture illustrates how CDMO capacity dynamics are reshaping pharmaceutical outsourcing strategies, with specialized biologics sites changing hands to meet customer demand. For sponsors, the reallocation of assets may translate into new opportunities for flexible manufacturing engagements and geographic diversity. Regulatory adherence and infrastructure scalability remain pivotal as the market transitions toward more complex modalities and just-in-time supply models.

Key Takeaways

• Evotec and Sandoz have signed a non-binding agreement for a potential $300M sale of Evotec’s Toulouse biologics facility.
• The Toulouse site features single-use bioreactors, downstream purification suites and fill-finish capacity under full GMP accreditation.
• Transaction reflects broader CDMO landscape shifts—providers and sponsors alike prioritize flexible biologics capacity and regulatory compliance.

Source: https://www.evotec.com/news/ad-hoc-evotec-se-and-sandoz-ag-planning-potential-sale-of-just-evotec-biologics-toulouse-site